On October 3, 2019, ProLung, Inc. (“ProLung” or the “Company”) and its long-time partner ProLung both whom are focused on reducing the time to diagnosis for lung cancer patients, proudly announced the results of a large clinical validation trial on its ProLung Test™ led by Professor Chunxue Bai at Fudan University. The study was sponsored by ProLung China and executed by its subsidiary, ProLung Biotech Wuxi, under the supervision of a Clinical Research Organization (CRO). In the study of 486 subjects with 418 effective, the ProLung Test returned results of 84% sensitivity, 74% specificity, 79% Positive Predictive Value (PPV) and 81% Negative Predictive Value (NPV). The ProLung Test’s performance from this clinical trial are the combined sensitivity and specificity values for a truly non-invasive solution that is pursuing FDA clearance for a lung cancer diagnostic that the Company is aware of. Furthermore, the ProLung Test is the only predictive analytic utilizing bioconductance in lung cancer. These trial results, along with the results of a soon to be started repeatability study, will underpin a future FDA de novo submission. Highlights from the trial include: Large clinical trial with 486 enrolled subjects; Uniformly high performance across all cancer stages, including very early stages of lung cancer; ProLung Test performance was effective across a wide range of lesion sizes ranging from 4-50mm; ProLung Test performance was outstanding in small lesions ranging from 4-8mm; ProLung Test was effective across a wide age range of 20-80 years; ProLung Test performance was effective in both male and female subjects.